Latest filing published 12 Jun 2026 for Cytek Biosciences, Inc..
Filing timeline
BuySaleInsider track record
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
Jack Ball: trading record in brief
Jack Ball, listed as board member, appears in our data through filings on Cytek Biosciences, Inc. shares, published by SEC (Form 4). We count 7 filings; the first trade dates from 22 July 2021 and the latest from 10 June 2026.
Market trades split into 1 purchase (€43k) and 1 sale (€228k). Sales outweigh purchases by €184k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 5 option exercises.
Most recently, on 12 June 2026, the filings show an option exercise in Cytek Biosciences, Inc. The clock since the last published purchase (27 July 2021) now reads 1,932 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Jack Ball
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 43,973 sharesCommon StockSEC:0001873083-26-000001:0
- 15,706 sharesCommon StockSEC:0001415889-25-016312:0
- 10,666 shares@ US$0.404.3% of flowCommon StockSEC:0001209191-22-059113:0
- 16,000 shares@ US$0.406.4% of flowCommon StockSEC:0001209191-22-057368:0
- 3,000 shares@ US$17.0080.8% of flowCommon StockSEC:0001209191-21-048388:0Canonical exit: 20 Oct 2021 (T+90)
5 of 5 declarations
